Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) reported its first-quarter 2021 earnings today after the closing bell. The revenue increased by 16% to $6.4 billion compared to the previous year. The net income was $1.72 billion or $1.37 per share compared to $1.55 billion or $1.22 per share of the same quarter in the previous […]
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) reported its first-quarter 2021 earnings today after the closing bell. The revenue increased by 16% to $6.4 billion compared to the previous year. The net income was $1.72 billion or $1.37 per share compared to $1.55 billion or $1.22 per share of the same quarter in the previous […]
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) reported its first-quarter 2021 earnings today after the closing bell.
The revenue increased by 16% to $6.4 billion compared to the previous year.
The net income was $1.72 billion or $1.37 per share compared to $1.55 billion or $1.22 per share of the same quarter in the previous year.
The adjusted earnings per share were $2.08 compared to $1.68 of the previous year.
